


PHARMACEUTICAL 2022

Werewolf Therapeutics Inc. Rank 174 of 475





PHARMACEUTICAL 2022

Werewolf Therapeutics Inc. Rank 174 of 475

The relative strengths and weaknesses of Werewolf Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Werewolf Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 146% points. The greatest weakness of Werewolf Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 44% points.

The company's Economic Capital Ratio, given in the ranking table, is -34%, being 243% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	161,068
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,874
Liabilities, Non-Current	14,589
Other Assets	15,269
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	104
Property and Equipment	2,913
Research and Development	35,269
Revenues	0
Selling, General and Administrative Expense	14,818

Output Variable	Value in 1000 USD
Assets	179,250
Liabilities	26,463
Expenses	50,087
Stockholders Equity	152,787
Net Income	-49,983
Comprehensive Net Income	-49,983
Economic Capital Ratio	-34%